What is Spyre Therapeutics, Inc.'s total liabilities & equity?

Spyre Therapeutics, Inc. (SYRE) reported total liabilities & equity of $763.95M in Q1 2026.

How has Spyre Therapeutics, Inc.'s total liabilities & equity changed year-over-year?

Spyre Therapeutics, Inc.'s total liabilities & equity increased by 34.1% year-over-year, from $569.78M to $763.95M.

What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities & equity?

Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities & equity has grown at a 36.9% compound annual growth rate (CAGR), from $161.62M to $777.78M.

Spyre Therapeutics, Inc. SYRE Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers SquibbBMY

$86.48B-6.4%

Eli LillyLLY

$116.58B+30.4%

PfizerPFE

$207.62B-0.2%

Johnson & JohnsonJNJ

$200.89B+3.7%

Merck & Co.MRK

$128.69B+11.8%

AbbVieABBV

$136.46B+0.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s total liabilities & equity?: Spyre Therapeutics, Inc. (SYRE) reported total liabilities & equity of $763.95M in Q1 2026.
How has Spyre Therapeutics, Inc.'s total liabilities & equity changed year-over-year?: Spyre Therapeutics, Inc.'s total liabilities & equity increased by 34.1% year-over-year, from $569.78M to $763.95M.
What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities & equity?: Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities & equity has grown at a 36.9% compound annual growth rate (CAGR), from $161.62M to $777.78M.